Active-targeting long-acting protein-glycopolymer conjugates for selective cancer therapy

Sun, Jiawei; Guo, Jianwen; Zhang, Longshuai; Gong, Like; Sun, Yuanzi; Deng, Xuliang; Gao, Wanzhen

doi:10.1016/j.jconrel.2023.02.046

Cited by 7 publications

(5 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…They found that this glucose-modified nanoparticle effectively inhibited GLUTs function and stimulated glucose deprivation and increased apoptotic enzyme expression. In a recent study by Sun et al [ 162 ], the ATRP copolymerization of glucose-containing methacrylate (GluMA) and OEGMA was used for the conjugation of interferon-α (IFN-α) for effective GLUTs targeting. The study outlined the importance of optimizing glucose content.…”

Section: Nanomedicines For Targeting Tme: Application Of Natural and ...mentioning

confidence: 99%

“…GLUT PLGA-chitosan particles GLUT-1 Glucose deprivation, increased apoptotic enzymes expression [161] Glucose-Methacrylate-OEGMA nanoparticles Interferon-α Tumor targeting and antitumor immunity [162] Cu particles/tumor cell membrane coating HIF-1α inhibitor/disulfiram Enhanced tumor sensitivity [167] Zn-imidazole-hyaluronic acid particles DNAzymes Antitumor effects inhibiting glucose energy [168] Nanopipette sensors Glucose Oxidase Identification of intracellular glucose level [169] Multidrug Resistance…”

Section: Targeting Effectsmentioning

confidence: 99%

See 1 more Smart Citation

Biomaterial-Based Responsive Nanomedicines for Targeting Solid Tumor Microenvironments

Avgoustakis,

Angelopoulou

2024

Pharmaceutics

View full text Add to dashboard Cite

Solid tumors are composed of a highly complex and heterogenic microenvironment, with increasing metabolic status. This environment plays a crucial role in the clinical therapeutic outcome of conventional treatments and innovative antitumor nanomedicines. Scientists have devoted great efforts to conquering the challenges of the tumor microenvironment (TME), in respect of effective drug accumulation and activity at the tumor site. The main focus is to overcome the obstacles of abnormal vasculature, dense stroma, extracellular matrix, hypoxia, and pH gradient acidosis. In this endeavor, nanomedicines that are targeting distinct features of TME have flourished; these aim to increase site specificity and achieve deep tumor penetration. Recently, research efforts have focused on the immune reprograming of TME in order to promote suppression of cancer stem cells and prevention of metastasis. Thereby, several nanomedicine therapeutics which have shown promise in preclinical studies have entered clinical trials or are already in clinical practice. Various novel strategies were employed in preclinical studies and clinical trials. Among them, nanomedicines based on biomaterials show great promise in improving the therapeutic efficacy, reducing side effects, and promoting synergistic activity for TME responsive targeting. In this review, we focused on the targeting mechanisms of nanomedicines in response to the microenvironment of solid tumors. We describe responsive nanomedicines which take advantage of biomaterials’ properties to exploit the features of TME or overcome the obstacles posed by TME. The development of such systems has significantly advanced the application of biomaterials in combinational therapies and in immunotherapies for improved anticancer effectiveness.

show abstract

Section: Nanomedicines For Targeting Tme: Application Of Natural and ...mentioning

confidence: 99%

Section: Targeting Effectsmentioning

confidence: 99%

Biomaterial-Based Responsive Nanomedicines for Targeting Solid Tumor Microenvironments

Avgoustakis,

Angelopoulou

2024

Pharmaceutics

View full text Add to dashboard Cite

show abstract

“…22 Carbohydrates play a significant role in biological processes such as recognition and signaling, [23][24][25][26][27] and they have a high affinity for proteins, making them suitable for applications that require target-specific binding. [28][29][30][31] Different carbohydrates have been used to identify bacteria. 32 For example, E. coli express FimH protein on their pili, allowing them to bind to glycopolymers on their surface.…”

Section: Introductionmentioning

confidence: 99%

In situ PET-RAFT polymerization to prepare guanidine-and-carbohydrate modified ZnO nanoparticles

Zhao,

Rao,

Zhang

et al. 2024

Polym. Chem.

View full text Add to dashboard Cite

show abstract

“…Studies have revealed that an excess of glucose initially induces TXNIP-mediated endocytosis of Glut1, followed by ubiquitination to support lysosomal transport . Upon interaction with specific macromolecules, such as protein–glycopolymer conjugates, Glut1 facilitates their internalization through the process of endocytosis . Besides, a research demonstrated that following the transport of cargo through endocytosis, Glut1 formed early endosomes, underwent maturation, and hydrolyzed the cargo along with a portion of Glut1.…”

Section: Introductionmentioning

confidence: 99%

“…26 Upon interaction with specific macromolecules, such as protein− glycopolymer conjugates, Glut1 facilitates their internalization through the process of endocytosis. 27 Besides, a research 28 Scheme 1. Glut1-Facilitated Lysosomal Degradation (GFLD) Strategy for Membrane or Extracellular Proteins Using Antibody−Glycooligomer Conjugate as Molecular Degrader a a The antibody−glycoside conjugates, known as molecular degraders, function by binding to the target PD-L1 protein, which is overexpressed on the membrane of the tumor cells.…”

Section: ■ Introductionmentioning

confidence: 99%

Lysosome Targeting Chimaeras for Glut1-Facilitated Targeted Protein Degradation

Luo,

Gao,

Tan

et al. 2024

J. Am. Chem. Soc.

View full text Add to dashboard Cite

Targeted protein degradation technology holds great potential in biomedicine, particularly in treating tumors and other protein-related diseases. Research on intracellular protein degradation using molecular glues and PROTAC technology is leading, while research on the degradation of membrane proteins and extracellular proteins through the lysosomal pathway is still in the preclinical stage. The scarcity of useful targets is an immense limitation to technological advancement, making it essential to explore novel, potentially effective approaches for targeted lysosomal degradation. Here, we employed the glucose transporter Glut1 as an innovative lysosome-targeting receptor and devised the Glut1-Facilitated Lysosomal Degradation (GFLD) strategy. We synthesized potential Glut1 ligands via reversible addition−fragmentation chain transfer (RAFT) polymerization and acquired antibody−glycooligomer conjugates through bioorthogonal reactions as lysosome-targeting protein degradation molecules, utilized in the management of PD-L1 high-expressing triple-negative breast cancer. The glucose transporter Glut1 as a lysosome-targeting receptor exhibits potential for the advancement of a broader array of medications in the future.

show abstract

Active-targeting long-acting protein-glycopolymer conjugates for selective cancer therapy

Cited by 7 publications

References 44 publications

Biomaterial-Based Responsive Nanomedicines for Targeting Solid Tumor Microenvironments

Biomaterial-Based Responsive Nanomedicines for Targeting Solid Tumor Microenvironments

In situ PET-RAFT polymerization to prepare guanidine-and-carbohydrate modified ZnO nanoparticles

Lysosome Targeting Chimaeras for Glut1-Facilitated Targeted Protein Degradation

Contact Info

Product

Resources

About